Cargando…

Day‐to‐day fasting self‐monitored blood glucose variability is associated with risk of hypoglycaemia in insulin‐treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials

AIMS: To investigate the association between day‐to‐day fasting self‐monitored blood glucose (SMBG) variability and risk of hypoglycaemia in type 1 (T1D) and type 2 diabetes (T2D), and to compare day‐to‐day fasting SMBG variability between treatments with insulin degludec (degludec) and insulin glar...

Descripción completa

Detalles Bibliográficos
Autores principales:	DeVries, J. Hans, Bailey, Timothy S., Bhargava, Anuj, Gerety, Gregg, Gumprecht, Janusz, Heller, Simon, Lane, Wendy, Wysham, Carol H., Zinman, Bernard, Bak, Britta A., Hachmann‐Nielsen, Elise, Philis‐Tsimikas, Athena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587774/ https://www.ncbi.nlm.nih.gov/pubmed/30362250 http://dx.doi.org/10.1111/dom.13565

Ejemplares similares

Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE
por: Heller, Simon, et al.
Publicado: (2020)

The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL
por: Philis‐Tsimikas, Athena, et al.
Publicado: (2020)

Development of a hypoglycaemia risk score to identify high‐risk individuals with advanced type 2 diabetes in DEVOTE
por: Heller, Simon, et al.
Publicado: (2020)

Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial
por: Chaykin, Louis, et al.
Publicado: (2019)

Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes
por: Philis-Tsimikas, Athena
Publicado: (2008)

Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
por: Philis-Tsimikas, Athena, et al.
Publicado: (2020)

Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)
por: Zinman, Bernard, et al.
Publicado: (2017)

Efficacy and Safety of Fast-Acting Insulin Aspart in People with Type 1 Diabetes Using Carbohydrate Counting: A Post Hoc Analysis of Two Randomised Controlled Trials
por: Rose, Ludger, et al.
Publicado: (2019)

Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2
por: Heller, Simon R., et al.
Publicado: (2019)

Investigating the day-to-day impact of hypoglycaemia in adults with type 1 or type 2 diabetes: design and validation protocol of the Hypo-METRICS application
por: Søholm, Uffe, et al.
Publicado: (2022)

Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial
por: Pieber, Thomas R., et al.
Publicado: (2021)

Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)
por: Zinman, Bernard, et al.
Publicado: (2012)

Predictors of glycemic control among patients with Type 2 diabetes: A longitudinal study
por: Benoit, Stephen R, et al.
Publicado: (2005)

Periodic Intensive Insulin Therapy Remains Experimental
por: Chang, Amy, et al.
Publicado: (2019)

Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use)
por: Philis-Tsimikas, Athena, et al.
Publicado: (2013)

Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase‐4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials
por: Janez, Andrej, et al.
Publicado: (2020)

A meta‐analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia
por: Heller, S., et al.
Publicado: (2015)

Digital health tools to promote diabetes education and management of cardiovascular risk factors among under-resourced populations
por: Paul, Tenes, et al.
Publicado: (2021)

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial
por: Rodbard, H W, et al.
Publicado: (2013)

A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges
por: King, Allen B., et al.
Publicado: (2017)

Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents
por: Philis-Tsimikas, A, et al.
Publicado: (2013)

When insulin degludec enhances quality of life in patients with type 2 diabetes: a qualitative investigation
por: Weatherall, James, et al.
Publicado: (2018)

Predictors of Dropouts From a San Diego Diabetes Program: A Case Control Study
por: Benoit, Stephen R., et al.
Publicado: (2004)

Hypoglycaemia in Type 2 diabetes
por: Amiel, S A, et al.
Publicado: (2008)

Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world setting
por: Seaquist, Elizabeth R., et al.
Publicado: (2018)

100 years on: the impact of the discovery of insulin on clinical outcomes
por: Buse, John B, et al.
Publicado: (2021)

Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial
por: Mathieu, Chantal, et al.
Publicado: (2018)

Improving Treatment of Depression Among Latinos With Diabetes Using Project Dulce and IMPACT
por: Gilmer, Todd P., et al.
Publicado: (2008)

Peer-Led Diabetes Education Programs in High-Risk Mexican Americans Improve Glycemic Control Compared With Standard Approaches: A Project Dulce promotora randomized trial
por: Philis-Tsimikas, Athena, et al.
Publicado: (2011)

Effects of Age on Glycemic Control in Patients With Type 2 Diabetes Treated with Insulin Detemir: A Post-Hoc Analysis of the PREDICTIVE™ 303 Study
por: Bhargava, Anuj, et al.
Publicado: (2016)

Cognitive deficits associated with impaired awareness of hypoglycaemia in type 1 diabetes
por: Hansen, Tor I., et al.
Publicado: (2017)

Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study
por: Wysham, Carol H, et al.
Publicado: (2020)

Evaluation of Hypoglycaemia with Non-Invasive Sensors in People with Type 1 Diabetes and Impaired Awareness of Hypoglycaemia
por: Elvebakk, Ole, et al.
Publicado: (2018)

A post‐hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla‐300) versus 100 U/mL (Gla‐100) over wider nocturnal windows in individuals with type 2 diabetes on a basal‐only insulin regimen
por: Bolli, Geremia B., et al.
Publicado: (2018)

Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add‐on to sodium‐glucose co‐transporter‐2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes
por: Philis‐Tsimikas, Athena, et al.
Publicado: (2019)

Memorable meals: The memory-experience gap in day-to-day experiences
por: Villinger, Karoline, et al.
Publicado: (2021)

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials
por: Ratner, R E, et al.
Publicado: (2013)

Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9)
por: Pollock, Richard F., et al.
Publicado: (2019)

Increased Derived Time in Range Is Associated with Reduced Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and Microvascular Events in Type 2 Diabetes: A Post Hoc Analysis of DEVOTE
por: Bergenstal, Richard M., et al.
Publicado: (2023)

The impact of hypoglycaemia awareness status on regional brain responses to acute hypoglycaemia in men with type 1 diabetes
por: Dunn, Joel T., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_neh0l0rkcp1ahu6d7jkss8l8rd